Human growth hormone-releasing factor

GH/IGF axis / recovery

Recovery, body composition, and anabolic signaling support

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: GH/IGF-axis peptide
Primary mechanism: Growth hormone / IGF pathway modulation
Primary market use: GH/IGF axis / recovery

Pharmacology

Molecular weight (Da): 5039.65
Oral bioavailability: Route-dependent / verify
Half-life: ~5–60 min parent peptide; analogs may be longer
Route tags: SubQ; Injectable; route-dependent
Evidence level: MCE product listing / research chemical signal
Clinical status: Research chemical/reference listing
Value-for-money score: 7 / 10

Reported protocol signal

No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Human growth hormone-releasing factor TFA (Growth Hormone Releasing Factor human TFA) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary.

Sources

https://www.medchemexpress.com/human-growth-hormone-releasing-factor-tfa.html